Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT00193219

Public ClinicalTrials.gov record NCT00193219. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer

Study identification

NCT ID
NCT00193219
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
SCRI Development Innovations, LLC
Other
Enrollment
36 participants

Conditions and interventions

Conditions

Interventions

  • Bevacizumab Drug
  • Cetuximab Drug
  • 5-fluorouracil Drug
  • Leucovorin Drug
  • Oxaliplatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2005
Primary completion
May 31, 2008
Completion
Jun 30, 2010
Last update posted
Jan 10, 2022

2005 – 2010

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Oncology Hematology Associates of SW Indiana Evansville Indiana 47714
Consultants in Blood Disorders and Cancer Louisville Kentucky 40207
Mercy Hospital Portland Maine 04101
Center for Cancer and Blood Disorders Bethesda Maryland 20817
Jackson Oncology Associates Jackson Mississippi 39202
St. Louis Cancer Care Chesterfield Missouri 63017
Methodist Cancer Center Omaha Nebraska 68114
Oncology Hematology Care Cincinnati Ohio 45242
Chattanooga Oncology and Hematology Associates Chattanooga Tennessee 37404
Tennessee Oncology Nashville Tennessee 37203

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00193219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 10, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00193219 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →